Previous Close | 4.0900 |
Open | 4.1100 |
Bid | 4.1600 x 800 |
Ask | 4.2400 x 1200 |
Day's Range | 4.0600 - 4.2400 |
52 Week Range | 2.6800 - 8.6200 |
Volume | |
Avg. Volume | 35,227 |
Market Cap | 29.786M |
Beta (5Y Monthly) | 1.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.6020 |
Earnings Date | Aug 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BPTH
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview. To access the live conferenc
DALLAS, TX / ACCESSWIRE / June 13, 2022 / Bio-Path Holdings, Inc. (Nasdaq:BPTH) The full report can be accessed by clicking on the following link: http://stonegateinc.
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments. “Throughout the first quarter, we continued to advance our missi